Aprea Therapeutics Inc (APRE)

NASDAQ

$0.67

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.

Website: https://aprea.com

Sector:

Healthcare

Industry:

Biotechnology

68 analysts

Strong Buy

Target: $4.30 (+542.75%)

Market Cap

$8.48M

P/B Ratio

0.21

Beta (5Y)

0.82

Price Chart

Adjust inflation

Log

Valuation

Market Cap$8.48M

P/S73.15

P/B0.21

Profitability

Gross Profit (TTM)-$6.05M

EBITDA-$13M

Operating Margin-10202%

EPS-$1.63

Growth & Risk

EPS 5Y CAGR-49.70%

FCF 5Y CAGR-23.47%

Beta (5Y)0.82

Sharpe Ratio-0.63